Acorda Therapeutics: Situation Getting Worse, Prompting A Restructuring [Seeking Alpha]
Acorda Therapeutics, Inc. (ACOR)
Last acorda therapeutics, inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acorda.com/investors
Company Research
Source: Seeking Alpha
Acorda Therapeutics: Situation Getting Worse, Prompting A Restructuring Summary Acorda Therapeutics pre-announced Q3 sales of Inbrija and Ampyra along with a restructuring plan. Ampyra's erosion has slowed down in recent quarters, but further declines are inevitable. Inbrija sales have grown modestly since launch and it doesn't seem like an adequate replacement for Ampyra. Restructuring leaves a lot to be desired - the revenue base is likely to shrink going forward while expenses remain too high. Acorda is not investable. ACOR wrote Inbrija disappoints again, Ampyra holding up (for now) Inbrija sales in Q3 reached $4.9 million, up from $3 million in Q2. The launch trajectory is clearly disappointing and not indicative of a drug capable of reaching hundreds of millions in net sales. In my previous article, I noted Inbrija sales need to reach $60-70 million a quarter for Acorda to reach cash flow breakeven or cash flow positive. And while the required number will go down due to the rest
Show less
Read more
Impact Snapshot
Event Time:
ACOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting Acorda Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics